Hayat Onyuksel, Ph.D.
 |
Professor, Pharmaceutics and Bioengineering Contact Information 833 South Wood Street 358 Pharm, MC 865 Chicago, IL 60612-7231 Office: (312) 996-2097 Fax: (312) 996-0098 Email: hayat@uic.edu |
Education
Postdoc - University of Michigan - 1980
Ph.D., Pharmaceutics - University of London - 1978
B.S., Pharmacy- University of Ankara- 1971
Research Interests
| Drug delivery using nanotechnology and nanomedicine (Related Publications) |
Novel treatment of Alzheimer's disease using PEGylated phospholipids (Related Publications) |
| Early detection and targeted chemotherapy of breast cancer (Related Publications) |
Phospholipid micelles as solubilizing agents, targeted drug carriers, and sensitizers of resistant cells (Related Publications) |
| Formulation and delivery of peptide and protein drugs using lipid-based carrier systems (Related Publications) |
Targeted therapy of rheumatoid arthritis (Related Publications) |
| Liposomes (StealthR, targeted and conventional) as drug delivery systems, ultrasound contrast agent and model membranes (Related Publications) |
Awards
| AAPS Lipid-Based Drug Delivery Outstanding Research Award (2008) |
UIC Graduate Mentoring Award (2008) | |
| UIC University Scholar (2008) |
AAPS Fellow (2006) | |
| UIC Woman of the Year (2003) | UIC Inventor of the Year (2003) |
Publications (2007-2013)
Banerjee A,Onyuksel H. A Novel Peptide Nanomedicine for Treatment of Pancreatogenic Diabetes. Nanomedicine: Nanotechnology, Biology, and Medicine, In press, 2013.
Sethi V., Rubinstein I., Kuzmis A., Artwohl J., Kastrissios H., and Onyuksel H. Novel, Biocompatible, Disease Modifying Nanomedicine of VIP for Rheumatoid Arthritis. Molecular Pharmaceutics, 10: 728-738, 2013 .
Dagar A., Kuzmis A., Rubinstein I., Sekosan M., Onyuksel H. VIP-targeted Cytotoxic Nanomedicine for Breast Cancer. Drug Deliv. and Transl.Res. 2: 454-462, 2012.
Lim S.B, Banerjee A,Onyuksel H. Improvement of drug safety by the use of Lipid-based Nanocarriers. J.Control.Release 163: 34-45, 2012.
Banerjee A, Onyuksel H. Peptide Delivery using Phospholipid Micelles. WIRE's Nanomed Nanobiotechnol 4(5):562-74, 2012
Banerjee A,Onyuksel H. Human Pancreatic Polypeptide in a Phospholipid Micellar Formulation. Pharm Res 29: 1698-1711, 2012.
Khaja F.A, Koo O., Onyuksel H. Nanomedicines for Inflammatory Diseases. Methods in Enzymology, Vol 508 Ed. Nejat Duzgunes, Burlington: Academic Press, Chapter 18, pp355-375, 2012.
Williams R.L, Lim S.B, Onyuksel H, Marucha P.T. Sterically Stabilized Phospholipid Micelles Reduce Activity of a Candidate Antimicrobial Wound Healing Adjunct. Int J Pept Res Ther. 18: 195-203, 2012.
Brandenburg K.S, Rubinstein I, Sadikot R.T, Onyuksel H. Polymyxin B Self-associated with Phospholipid Nanomicelles. Pharm. Dev. and Tech.,17: 654–660, 2012 DOI
Vukovic L, Khatib F, Drake S, Madriaga A, Brandenburg K, Kral P, and Onyuksel H. Structure and Dynamics of Highly PEGylated Sterically Stabilized Micelles in Aqueous Media.J Am Chem Soc. 133:13481-13488, 2011.
Onyuksel H, Banerjee A . Phospholipid–based Nanomicelles in Cancer Nanomedicine. Nanomedicine in Health and Disease, Eds Hunter R.J and Preedy V.R. CRS Press, Chapter 16, pages 314-335, 2011.
Kuzmis A, Lim SB, Desai E, Jeon E, Lee BS, Rubinstein I, Onyuksel H. Micellar Nanomedicine of Human Neuropeptide Y. Nanomedicine. 2011 Aug; 7(4): 464-71. Epub 2011 Jan 25. DOI
Koo MY, Rubinstein I, Onyuksel H. Actively Targeted Low-Dose Camptothecin as a Safe, Long-Acting, Disease Modifying Nanomedicine for Rheumatoid Arthritis. Pharm Res. 28:776-787, 2011. DOI
Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Onyuksel H. A Novel Peptide Nanomedicine Against Acute Lung Injury:GLP-1 in Phospholipid Micelles Pharm Res. 28:662-672, 2011. DOI
Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009 Jun;5(2):178-83. Epub 2008 Dec 13. DOI
Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009 Feb 18;274(2):327-30. Epub 2008 Nov 20. DOI
Onyuksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: A novel targeted nanomedicine for breast cancer. Int J Pharm. 2009 Jan 5;365(1-2):157-61. Epub 2008 Aug 27. DOI
Lu E, Franzblau S, Onyuksel H, Popescu C. Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion. J Microencapsul. 2008 Aug 21:1-9. [Epub ahead of print]. DOI
Sethi V, Rubinstein I, Dudeja P.K, Weinberg G, Onyuksel H. Biphasic Behavior of Bupivacaine and Cardiolipin-Containing Biomimetic Membrane Interaction J. Drug Del. Sci. Tech, 18: 69-72, 2008.
Lim SB, Rubinstein I, Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int J Pharm. 2008 May 22;356(1-2):345-50. Epub 2008 Jan 17. DOI
Rubinstein I, Soos I, Onyuksel H. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem Biol Interact. 2008 Jan 30;171(2):190-4. Epub 2007 Apr 6. DOI
Numanoglu U, Sen T, Tarimci N, Kartal M, Koo OM, Onyuksel H. Use of cyclodextrins as a cosmetic delivery system for fragrance materials: linalool and benzyl acetate. AAPS Pharm Sci Tech. 2007;8(4):E85. DOI
Rubinstein I, Onyuksel H. Biocompatible biodegradable and sterically stabilized phospholipid nanomicelles improve cryopreservation of oral keratinocytes: A peliminary investigation : Int. J. Pharm. 2007;338:333-5. DOI
Klegerman ME, Huang S, Parikh D, Martinez J, Demos S, Onyuksel H,McPherson D. Lipid contribution to the affinity of antigen association with specific antibodies conjugated to liposomes. Biochimica et Biophysica Acta. 2007;1768:1703-16. DOI
Onyuksel H, Sethi V, Weinberg G.L, Dudeja P.K, Rubinstein I. Bupivacain, but not lidocain, disrupts cardiolipin - containing small biomimetic unilamellar liposomes. Chem Biol Inter. 2007;169:154-9. DOI
Wang H, Onyuksel H, Gulati A, Rubinstein I. Self-association of endothelin-1 with sterically stabilized phospholipid nanomicelles amplifies its hemodynamic effects in Rats. J Biomed Nanotechnol. 2007;3:270 DOI
Koo O, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid nano-micelles: A novel solvent pH change solubilization method. J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2996-3000.
Pai A, Rubinstein I, Onyuksel H. PEGylated phospholipid micelles interact with beta amyloid (1-42) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. Peptides. 2006 Nov;27(11):2858-66. Epub 2006 Jun 9. DOI
Onyuksel H, Séjourné F, Suzuki H, Rubinstein I. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. Peptides. 2006 Sep;27(9):2271-5. Epub 2006 Apr 18. DOI
Rubinstein I, Ikezaki H, Onyuksel H. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in hypertensive hamsters. Int J Pharm. 2006 Jun 19;316(1-2):144-7. Epub 2006 Mar 6. DOI
Lu J, Jeon E, Lee BS, Onyuksel H, Wang ZJ. Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J Control Release. 2006;110(3):505-513. DOI
Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005 Sep;1(3):193-212. DOI
Arleth L, Ashok B, Onyuksel H, Thiyagarajan P, Jacob J, Hjelm RP. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir. 2005;21(8):3279-90. DOI
Sethi V, Onyuksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 2005;391:377-95. DOI
Rubinstein I, Ashok B, Tsueshita T, Onyuksel H. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo. Peptides. 2005 Mar;26(3):509-15. DOI
Koo OM, Rubinstein I, Onyuksel H. Camptothecin in Sterically Stabilized Phospholipid Micelles: A Novel Nanomedicine. J. Nanomedicine. 2005 Sep;1:77-84. DOI